

[Open Peer Review on Qeios](#)

Polyvalent Antigen-KLH Conjugate Vaccine

National Cancer Institute

Source

National Cancer Institute. *Polyvalent Antigen-KLH Conjugate Vaccine*. NCI Thesaurus. Code C77870.

A multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, T n-MUC1, T F, and sT n conjugated with the immunoadjuvant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Upon administration, polyvalent antigen-KLH conjugate vaccine may induce production of IgG and IgM antibodies and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these TAAs, resulting in tumor cell death and tumor growth inhibition. Globo H (globo H hexasaccharide 1); GM2 ganglioside; T n-MUC1 (human tumor-associated epithelial mucin 1 carrying the tumor-specific glycan T n); T F (Thompson-Friedreich); and sT n (sialyl-T n) are overexpressed in a variety of cancer cells. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition of antigens.